IP Library Granted Patent US 12661383
Granted Patent B2
US 12661383 · App. 18/305,899 · Granted Jun 23, 2026

Proteins for the treatment of epithelial barrier function disorders

Inventors: Andrew Wonhee Han (San Francisco, CA); Andrew Whitman Goodyear (Pacifica, CA); Tarunmeet Gujral (Foster City, CA); Todd Zachary DeSantis (Livermore, CA); Karim Dabbagh (Mountain View, CA); Toshihiko Takeuchi (Oakland, CA); Ye Jin (Danville, CA); Michi Izumi Willcoxon (Palo Alto, CA); Stefanie Banas (Concord, CA)
Assignee: Genevive, Inc.
A61K38/16A61P1/04A61P37/02C07K2/00C07K14/195A61K38/00C07K14/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661383
App. No.
18/305,899
Granted
Jun 23, 2026
Kind
B2
Abstract

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Claims (13)

1 . A synthetic protein, comprising: an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 19, wherein the amino acid at position 147 is not cysteine and/or the amino acid at position 151 is not cysteine.

2 . The synthetic protein of claim 1 , wherein the amino acid at position 147 is valine.

3 . The synthetic protein of claim 1 , wherein the amino acid at position 151 is serine.

4 . The synthetic protein of claim 1 , wherein the amino acid at position 147 is valine, and the amino acid at position 151 is serine.

5 . The synthetic protein of claim 1 , wherein the amino acid at position 84 is aspartic acid.

6 . The synthetic protein of claim 1 , wherein the amino acid at position 84 is aspartic acid, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.

7 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is serine.

8 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is serine, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.

9 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine.

10 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine, and the amino acid at position 84 is aspartic acid, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.

11 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine, and the amino acid at position 83 is serine, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.

12 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is not asparagine and/or the amino acid at position 53 is not asparagine.

13 . A pharmaceutical composition, comprising: the synthetic protein of claim 1 and a pharmaceutically acceptable carrier.